These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 25382021)
21. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Rodrigo GJ; Neffen H Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684 [TBL] [Abstract][Full Text] [Related]
23. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA COPD; 2018; 15(4):334-340. PubMed ID: 30265816 [TBL] [Abstract][Full Text] [Related]
24. Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses. Iqbal A; Barnes NC; Brooks J Clin Drug Investig; 2015 Oct; 35(10):685-8. PubMed ID: 26329916 [TBL] [Abstract][Full Text] [Related]
25. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. Mehta R; Hardes K; Kelleher D; Preece A; Tombs L; Brealey N Clin Ther; 2014 Jul; 36(7):1016-1027.e2. PubMed ID: 24947493 [TBL] [Abstract][Full Text] [Related]
26. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872 [TBL] [Abstract][Full Text] [Related]
27. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Kelleher D; Tombs L; Preece A; Brealey N; Mehta R Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273 [TBL] [Abstract][Full Text] [Related]
28. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease. Parri G; Nieri D; Roggi MA; Vagaggini B; Celi A; Paggiaro P Expert Rev Respir Med; 2018 Dec; 12(12):997-1005. PubMed ID: 30463451 [No Abstract] [Full Text] [Related]
29. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Mehta R; Kelleher D; Preece A; Hughes S; Crater G Int J Chron Obstruct Pulmon Dis; 2013; 8():159-67. PubMed ID: 23569370 [TBL] [Abstract][Full Text] [Related]
30. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Maltais F; Singh S; Donald AC; Crater G; Church A; Goh AH; Riley JH Ther Adv Respir Dis; 2014 Dec; 8(6):169-81. PubMed ID: 25452426 [TBL] [Abstract][Full Text] [Related]
31. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Bollmeier SG; Prosser TR Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654 [TBL] [Abstract][Full Text] [Related]
32. The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study. Requena G; Dedman D; Quint JK; Ghosh RE; Williams R; Pimenta JM Int J Chron Obstruct Pulmon Dis; 2021; 16():629-642. PubMed ID: 33731992 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Bjermer LH; Boucot IH; Vogelmeier CF; Maltais F; Jones PW; Tombs L; Compton C; Lipson DA; Kerwin EM Adv Ther; 2021 Sep; 38(9):4815-4835. PubMed ID: 34347255 [TBL] [Abstract][Full Text] [Related]
35. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease. Condreay L; Huang L; Harris E; Brooks J; Riley JH; Church A; Ghosh S Respir Med; 2016 May; 114():123-6. PubMed ID: 27109822 [TBL] [Abstract][Full Text] [Related]
36. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Tabberer M; Jones CE; Kilbride S; Halpin DMG; Lomas DA; Pascoe S; Singh D; Wise RA; Criner GJ; Lange P; Dransfield MT; Han MK; Martinez FJ; Kaisermann MC; Lipson DA Adv Ther; 2020 Sep; 37(9):3775-3790. PubMed ID: 32647911 [TBL] [Abstract][Full Text] [Related]
37. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468 [TBL] [Abstract][Full Text] [Related]
38. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD. Singh S; Maltais F; Tombs L; Fahy WA; Vahdati-Bolouri M; Locantore N; Riley JH Int J Chron Obstruct Pulmon Dis; 2018; 13():203-215. PubMed ID: 29386889 [TBL] [Abstract][Full Text] [Related]
39. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. Ramadan WH; Al Masri S; Rizk J Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190 [TBL] [Abstract][Full Text] [Related]
40. A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis". Ismaila AS; Haeussler K; Malmenäs M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG Adv Ther; 2023 May; 40(5):2556-2561. PubMed ID: 37004642 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]